Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: A Gross Profit Performance Breakdown

Pharma Giants' Gross Profit: A Decade of Divergence

__timestampCorcept Therapeutics IncorporatedTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20142566900011056000000
Thursday, January 1, 20154892500011356000000
Friday, January 1, 20167926300011859000000
Sunday, January 1, 201715564700010825000000
Monday, January 1, 20182460320008296000000
Tuesday, January 1, 20193009820007536000000
Wednesday, January 1, 20203482920007725000000
Friday, January 1, 20213606970007594000000
Saturday, January 1, 20223964730006973000000
Sunday, January 1, 20234758940007646000000
Monday, January 1, 20248064000000
Loading chart...

Unleashing insights

A Tale of Two Pharmaceutical Giants: Gross Profit Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, Teva Pharmaceutical Industries Limited and Corcept Therapeutics Incorporated have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, Teva's gross profit has seen a decline of approximately 31%, dropping from its peak in 2016. This trend reflects the challenges faced by the company in maintaining its market dominance.

Conversely, Corcept Therapeutics has experienced a remarkable growth, with its gross profit surging by over 1,750% during the same period. This impressive increase highlights Corcept's strategic advancements and successful market penetration.

The data underscores the dynamic nature of the pharmaceutical industry, where innovation and strategic positioning can lead to significant financial outcomes. As we look to the future, these trends offer valuable insights into the evolving strategies of these industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025